Skip to main content
Mega Genomics Limited logo

Mega Genomics Limited — Investor Relations & Filings

Ticker · 6667 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 317 across all filing types
Latest filing 2025-04-22 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 6667

About Mega Genomics Limited

https://www.megagenomics.cn

Mega Genomics Limited operates as a genetic testing platform company focused on providing consumer genetic testing and cancer screening services. The core business involves delivering comprehensive genetic analysis solutions to the consumer market. Key product offerings include advanced sequencing packages such as Personal Whole Genome Sequencing, which analyzes over 700,000 genetic loci to assess disease risk and provide pharmacogenomic recommendations. Additionally, the company offers Adult and Children's Whole Exome Sequencing packages, which analyze over 180,000 key exome regions to evaluate risks for high-risk diseases, hereditary cancers, and complex genetic disorders, alongside personalized guidance on drug efficacy, nutrition, and fitness.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION (1) SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS ANNOUNCEMENT&#x3b; AND (2) CONTINUED SUSPENSION OF TRADING
Report Publication Announcement Classification · 1% confidence The document is a regulatory announcement by a Hong Kong‐listed company about the delay in the publication of its 2024 Annual Results and continued trading suspension. It does not contain the full annual report or financial data itself, but rather informs shareholders of the timing and status of the report’s release. This fits the definition of a Report Publication Announcement (RPA).
2025-04-22 English
INSIDE INFORMATION (1) DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024&#x3b; (2) POSTPONEMENT OF THE BOARD MEETING&#x3b; AND (3) SUSPENSION OF TRADING
Report Publication Announcement Classification · 1% confidence The document is an "Inside Information" announcement under the Hong Kong Listing Rules announcing a delay in the publication of the annual results for the year ended 31 December 2024, a postponement of the Board meeting to approve those results, and suspension of trading pending the release of the annual results. It does not contain the results themselves but addresses the timing and publication of a report. This matches the definition of a Report Publication Announcement (RPA).
2025-04-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025
Transaction in Own Shares Classification · 1% confidence The document is a statutorily required monthly return under HKEX Listing Rules detailing movements in share capital, issuance, treasury shares, and notably share repurchases and cancellations for the month ended 31 March 2025. This is not an Annual Report, Earnings Release, or proxy material, but a detailed report of the company’s own share transactions (repurchases). According to the filing definitions, such a report falls under “Transaction in Own Shares” (POS).
2025-04-01 English
EXCHANGE NOTICE - SUSPENSION OF TRADING
Delisting Announcement Classification · 1% confidence The document is a short notice from the Hong Kong Stock Exchange (HKEX) announcing the suspension of trading for Mega Genomics Limited. It does not contain financial statements, management reports, or proxy materials. Since it is a regulatory announcement regarding trading status that does not fit into specific categories like delisting or share issuance, it falls under the general regulatory filings category.
2025-04-01 English
INSIDE INFORMATION (1) DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024&#x3b; (2) POSTPONEMENT OF THE BOARD MEETING&#x3b; AND (3) SUSPENSION OF TRADING
Report Publication Announcement Classification · 1% confidence The document is a short announcement by a listed company under HK Listing Rules informing investors of the delay in publishing its 2024 Annual Results, the postponement of the board meeting to approve those results, and the suspension of trading pending release. It does not contain the actual annual results or detailed financial data, nor is it a full annual or interim report. Instead, it is purely an announcement about the timing and publication status of a report. This matches the definition of Report Publication Announcement (RPA).
2025-04-01 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a “Next Day Disclosure Return” (Form FF305) under the Hong Kong Stock Exchange listing rules detailing share repurchases and changes in issued shares/treasury shares. It provides the dates, numbers of shares repurchased and cancelled, and confirmation by a director. This matches a report of the company buying back its own shares, which corresponds to the “Transaction in Own Shares” category.
2025-03-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.